The Hsp90 inhibitor 17-allylaminogeldanamycin (17-AAG), which is currently in clinical trials, is thought to exert antitumor activity by simultaneously targeting several oncogenic signaling pathways. Here we report a novel mechanism by which 17-AAG inhibits cell proliferation, and we provide the first evidence that HSP90 is required for the assembly of kinetochore protein complexes in humans. 17-AAG caused delocalization of several kinetochore proteins including CENP-I and CENP-H but excluding CENP-B and CENP-C. Consistently, 17-AAG induced a mitotic arrest that depends on the spindle checkpoint and induced misalignment of chromosomes and aneuploidy. We found that HSP90 associates with SGT1 (suppressor of G2 allele of skp1; SUGT1) in human cells and that depletion of SGT1 sensitizes HeLa cells to 17-AAG. Overexpression of SGT1 restored the localization of specific kinetochore proteins and chromosome alignment in cells treated with 17-AAG. Biochemical and genetic results suggest that HSP90, through its interaction with SGT1 (SUGT1), is required for kinetochore assembly. Furthermore, timecourse experiments revealed that transient treatment with 17-AAG between late S and G2/M phases causes substantial delocalization of CENP-H and CENP-I, a finding that strongly suggests that HSP90 participates in kinetochore assembly in a cell cycle-dependent manner.
Introduction
HSP90 is a molecular chaperone involved in the folding, assembly, maturation, and stabilization of specific target proteins (often called 'HSP90 clients'), and HSP90 performs these functions in different complexes containing various cochaperones (Goetz et al., 2003; Neckers and Ivy, 2003; Workman, 2003) . The benzoquinone ansamycin geldanamycin (GA) binds to a conserved binding pocket in the N-terminal domain of HSP90 (Prodromou et al., 1997; Stebbins et al., 1997 ). Geldanamycin's binding to HSP90 inhibits ATP binding and ATP-dependent chaperone activity (Obermann et al., 1998; Panaretou et al., 1998; Grenert et al., 1999) . The GA derivative 17-allylaminogeldanamycin (17-AAG) has shown antitumor activity in several human xenograft models (Kelland et al., 1999; Basso et al., 2002; Solit et al., 2002) . The antitumor activity of 17-AAG is thought to result from its simultaneous targeting of several oncogenic signaling pathways and its sensitizing of cells to chemotherapeutic agents (Goetz et al., 2003; Neckers and Ivy, 2003; Workman, 2003) . Recently, Phase I clinical trials of 17-AAG were successfully completed (Beliakoff and Whitesell, 2004; Goetz et al., 2005) . Geldanamycin and 17-AAG induce G1 and G2/M arrest (Srethapakdi et al., 2000; Hostein et al., 2001; Munster et al., 2001; Nimmanapalli et al., 2001; Arlander et al., 2003) . Although the mechanism by which 17-AAG causes G1 arrest has been well characterized, that of G2/M arrest remains obscure (de Carcer, 2004) .
The kinetochore, which consists of DNA elements and structural proteins, is essential for high-fidelity transmission of chromosomes during cell division. In the budding yeast Saccharomyces cerevisiae, Hsp90 is required for the assembly of the kinetochore's core complex, CBF3 (Stemmann et al., 2002) . CBF3 consists of the important proteins p110 (encoded by NDC10/ CTF14/CBF2), p64 (encoded by CEP3/CBF3b), p58 (encoded by CTF13) (Lechner and Carbon, 1991; Doheny et al., 1993; Goh and Kilmartin, 1993; Jiang et al., 1993; Lechner, 1994; Strunnikov et al., 1995; Connelly and Hieter, 1996; Stemmann and Lechner, 1996) , and Skp1 (Connelly and Hieter, 1996; Stemmann and Lechner, 1996) . Sgt1 and Skp1 are required for CBF3 assembly via Ctf13 activation (Kaplan et al., 1997; Kitagawa et al., 1999) . In yeast, the interaction between Hsp90 and Sgt1 is also required for kinetochore assembly (Bansal et al., 2004; Lingelbach and Kaplan, 2004 ).
Human centromere DNA, which consists of repetitive alpha-satellite sequences that are several kilobases to megabases long, is very different from that of the yeast point centromere, and yeast CBF3 is not conserved in humans (Kitagawa and Hieter, 2001; Biggins and Walczak, 2003) . However, some inner (e.g., CENP-C), central (e.g., CENP-H and CENP-I), and outer kinetochore proteins (e.g., HEC1) and the spindle checkpoint components (e.g., BUB1 and MAD2) are conserved (Kitagawa and Hieter, 2001; Biggins and Walczak, 2003) . Human SGT1 (SUGT1) can rescue the sgt1-null mutant (Kitagawa et al., 1999) , a result that suggests that the function of SGT1 is conserved in humans and yeast. This hypothesis is also supported by the finding that CENP-I, CENP-F, and HEC1, but not CENP-C, are absent from kinetochores in SGT1-depleted human cells (Steensgaard et al., 2004) . However, the role of HSP90 at human kinetochores has not been explored.
Here, we show that inhibition of HSP90 by 17-AAG treatment or by use of HSP90 small-interfering RNA (siRNA) prevents several kinetochore proteins from localizing at the kinetochores, which results in mitotic arrest that depends on the spindle checkpoint, in misalignment of chromosomes, and in aneuploidy. Genetic and biochemical data suggest that HSP90 functions, via SGT1, at human kinetochores. Thus, we have identified a novel mechanism by which 17-AAG inhibits cell proliferation.
Results
Inhibition of HSP90 by 17-AAG or siRNA prevents the kinetochore localization of several kinetochore proteins To explore the role of HSP90 at kinetochores in human cells, we examined the effect of the Hsp90 inhibitor 17-AAG on the localization of known kinetochore proteins. The kinetochore localization of CENP-H (a central kinetochore protein) was substantially reduced in HeLa cells treated with 17-AAG (at 10, 100, 500, 800, and 1000 nM) for 24 h (Figure 1  a, d , and e). As concentrations higher than 500 nM were cytotoxic and we could see substantial effects at 500 nM, we decided to use 500 nM for further analyses. During prophase, prometaphase, and metaphase, the kinetochore localization of CENP-H, and CENP-I (a central kinetochore protein) was substantially reduced in HeLa cells treated with 17-AAG (Figure 1a , b, and e). Interestingly, the kinetochore localization of BUBR1 (a spindle checkpoint component), CENP-E (a kinesin-like motor protein and an outer kinetochore protein), and HEC1 (an outer kinetochore protein) in treated cells was reduced substantially at metaphase but only moderately at prophase and prometaphase (Figure 1e and Supplementary Figure S1a -c). The kinetochore localization of BUB1 (a spindle checkpoint protein) during mitosis was moderately reduced (Figure 1e and Supplementary Figure S1d ).
Treatment with 17-AAG (500 nM for 24 h) did not substantially affect the localization of kinetochore proteins detected by CREST, an anticentromere antibody that originated from patients with CREST and that detects mainly CENP-A, CENP-B (an inner heterochromatin kinetochore protein), and CENP-C (an inner/central plate kinetochore protein) (Figure 1a-c) . Consistently, the kinetochore localization of CENP-C and CENP-B was not substantially affected ( Figure 1c and e and Supplementary Figure S1e) . These results suggest that the core structure (at least part) of the kinetochore remains intact in 17-AAG-treated cells.
The degradation of Hsp90 client proteins is induced by 17-AAG (Neckers, 2002; Goetz et al., 2003; Workman, 2003) . By conducting immunoblot analyses, we determined whether kinetochore proteins are degraded in 17-AAG-treated human cells. The amounts of the tested kinetochore proteins (BUB1, BUBR1, CENP-B, CENP-E, CENP-H, CENP-I, and HEC1) were not substantially reduced in the 17-AAG-treated cells (Supplementary Figure S1f) .
Our results indicate that the HSP90 inhibitor 17-AAG induces the delocalization of several kinetochore proteins and suggest that HSP90 is required for the localization of these proteins to the kinetochore. To test this hypothesis, we performed HSP90 siRNA experiments. Depletion of HSP90alpha and HSP90beta, together but not individually, by specific siRNA prevented the kinetochore localization of CENP-H, CENP-I, and BUB1 but did not prevent that of CENP-B and CENP-C (Figure 2a-d, Supplementary Figure S2 , and data not shown). The proteins whose localization to the kinetochore was prevented by HSP90 siRNA are the same as those whose localization was prevented by 17-AAG (Figures 1e, 2d and Supplementary  Table 2 ). Furthermore, simultaneous HSP90 siRNA and 17-AAG treatment yielded results similar to those yielded by either treatment alone (Supplementary Figure S2c) . Together, these results indicate that HSP90 inhibition by 17-AAG delocalizes several kinetochore proteins, a conclusion that strongly suggests that HSP90 is required for kinetochore assembly in human cells.
Hsp90 is required for kinetochore assembly only from late S phase to G2/M phase We examined whether transient treatment with 17-AAG at particular stages of the cell cycle is sufficient to cause the delocalization of kinetochore proteins. We performed a time-course experiment by using a doublethymidine block to arrest the cell cycle of HeLa cells and by releasing the cell cycle from the G1/S phase ( Figure 3a ) (Tatsumi et al., 2003) . Cells were then exposed to 17-AAG (500 nM) only for 2 h in each time frame (2-4, 4-6, 6-8, 8-10, and 10-12 h) . When cells were treated with 17-AAG at the 6-8-h time point (late S phase to G2/M phase, lane C) (Tatsumi et al., 2003) , the kinetochore localization of CENP-H and CENP-I was substantially reduced (Figure 3b and c) . These results indicate that HSP90 is required for the To test whether 17-AAG can affect 'established' kinetochores, we treated cells with nocodazole (a microtubule-depolymerizing drug) or paclitaxel (Taxol, a microtubule-stabilizing drug) to arrest the cell cycle at prometaphase or metaphase (when the kinetochore is supposed to be established for chromosome segregation). We then treated the cells with 17-AAG for 2 h. We saw no substantial reduction in the kinetochore localization of CENP-H or CENP-I in the 17-AAG-treated mitotic cells (Figure 3b and c, lanes N and T). These results suggest that 17-AAG does not affect established kinetochores that are ready to separate during metaphase. We conclude that HSP90 is required for kinetochore assembly in a cell cycledependent manner but is not required for kinetochore maintenance.
Inhibition of HSP90 by 17-AAG induces chromosome misalignment and aneuploidy To investigate the consequence of the kinetochore defects induced by 17-AAG treatment, we monitored chromosome misalignment, which we presumed would be caused by kinetochore defects. We counted cells that had several misaligned chromosomes (see Figure 3d for examples). Consistent with the delocalization of kinetochore proteins was our finding that 17-AAG treatment increased the occurrence of 'moderate' misalignment by a factor of approximately 9 (Figure 3e ).
We also counted chromosomes in 17-AAG-treated HCT116 cells, which we used because they have relatively normal karyotypes. Treatment with 17-AAG (500 nM for 24 h) caused 'moderate' aneuploidy ( Figure 3f ), consistent with the moderate chromosome misalignment seen in treated HeLa cells.
Consistent with the mitotic defects we observed, a substantial number of 17-AAG-treated HeLa cells were in prophase, prometaphase, and metaphase as shown by microscopic examination after staining with 4,6-diamidino-2-phenylindole (DAPI). This observation indicates that 17-AAG treatment (500 nM for 24 h) induces a mitotic delay (approximately 27% of the cells were mitotic). As arrest at early mitotic stages suggests the involvement of the spindle checkpoint, we examined whether mitotic arrest induced by 17-AAG depends on the spindle checkpoint. A checkpoint component, MAD2, was depleted from HeLa cells by using synthetic siRNA, and the cells were incubated in the presence of 17-AAG. Depletion of MAD2 diminished the mitotic delay induced by 17-AAG (will be described elsewhere). These results strongly suggest that the mitotic arrest induced by 17-AAG depends on the spindle checkpoint.
HSP90 associates with SGT1 in human cells
As Hsp90 associates with Sgt1, and the Sgt1-Hsp90 complex is required for the assembly of CBF3 in budding yeast (Bansal et al., 2004) , we determined whether HSP90 associates with SGT1 in human cells. In an immunoprecipitation and mass spectrometry analysis, proteins were precipitated from HeLa cell extracts by anti-SGT1 antibody or mouse IgG (a negative control), and HSP90alpha, HSP90beta, and HSC70 were identified as SGT1-interacting proteins by mass spectrometry (Figure 4a and Supplementary Figure S3a and b). The specificity of the immunoprecipitation was confirmed by Western blot analysis ( Figure 4b ). HSP90 was specifically found in the SGT1 immunoprecipitate ( Figure 4b ). As HSC70 was found in the control IgG as well as the SGT1 immunoprecipitate (Figure 4b ), we could not conclude that HSC70 interacts with SGT1. SKP1 was present specifically in the SGT1 immunoprecipitate (Figure 4b ), a result consistent with our previous finding in yeast (Kitagawa et al., 1999) .
In a reciprocal experiment, we found SGT1 in the HSP90 immunoprecipitate ( Figure 4c ). These results indicate that SGT1 forms a complex with HSP90 in human cells, a finding consistent with the earlier observation that 17-AAG treatment (Figure 1 ), HSP90 siRNA ( Figure 2 ), and SGT1 siRNA (Steensgaard et al., 2004) can cause the delocalization of kinetochore proteins.
Interestingly, 17-AAG inhibited the HSP90-SGT1 association ( Figure 4d ). The decreased interaction between HSP90 and SGT1 was not a result of the mitotic delay induced by 17-AAG, because treatment with the microtubule inhibitor 3-(1-anilinoethylidene)-5-benzylpyrrolidine-2,4-dione (also known as TN16) did not affect the HSP90-SGT1 association ( Figure 4e ). These results suggest that the kinetochore defect in 17-AAG-treated cells is due to the absence of the HSP90-SGT1 association. In addition, the HSP90-SGT1 association was unaffected by the doublethymidine block treatment (Figure 4e ), a finding that suggests that the HSP90-SGT1 interaction occurs throughout the cell cycle.
HSP90 and SGT1 function together to assemble the kinetochore in humans To determine whether kinetochore defects caused by 17-AAG are related to the function of SGT1, we examined the viability of cells depleted of SGT1 ( Figure 5c ) and treated (or not) with 17-AAG by using the TUNEL assay ( Figure 5a ) and a colony outgrowth Immunolabeling with CREST antiserum (red) and DAPI staining (blue) revealed the position of the kinetochore region. Although the CREST signal remained at the kinetochore, the CENP-H signal (green) was absent from the kinetochore in HSP90-depleted cells at prophase, metaphase, and interphase. (b) The CENP-I signal at the kinetochore during prophase, metaphase, and interphase was also diminished by HSP90 depletion, but (c) the CENP-C signal at the kinetochore during prophase, metaphase, and interphase was unaffected by HSP90 depletion. (d) The kinetochore signals of the indicated proteins in HSP90-depleted cells in prophase (blue bars), metaphase (red bars), or interphase (yellow bars) were normalized to that of the same protein in untreated cells, and the amount of signal retained after HSP90 siRNA treatment is presented as 'Remaining kinetochore signals' (%). (e) Western blot analysis of HeLa cell lysates harvested 72 h after cotransfection with siRNA duplexes directed against HSP90alpha and HSP90beta revealed depletion of HSP90alpha and HSP90beta (the antibody recognizes both HSP90alpha and HSP90beta). Cells transfected with luciferase (Luc) siRNA served as a negative control. GAPDH protein served as a control for loading. (Tatsumi et al., 2003) and then incubated with (i) 17-AAG for 2 h at different time points (2-4, 4-6, 6-8, 8-10, and 10-12 h) or (ii) nocodazole (N) or paclitaxel (T) for 6 h (6-12 h), then 17-AGG for 2 h (12-14 h). The FACS profiles of cells after their release from the double-thymidine block (0-12 h) are shown. (b, c) At 12 h after the cells' release from G1/S arrest, we quantified the kinetochore signals of CENP-H (b) and CENP-I (c) in cells at prophase (blue bars), metaphase (red bars), and interphase (yellow bars) that had been treated with 17-AAG for 2 h at the time points shown. The amount of signal remaining at the kinetochore after 17-AAG treatment is expressed as a percentage of that seen at the kinetochore in untreated cells. The greatest reduction in the CENP-H and CENP-I signals occurred in the samples treated with 17-AAG at 6-8 h (late S phase to early G2 phase) (lane C). Cells treated with nocodazole (N) or paclitaxel (T) before 17-AAG treatment were also tested 14 h after release from G1/S arrest. We analysed a total of 100 cells in each category. In a reciprocal experiment, overexpression of SGT1A restored the kinetochore localization of CENP-H, CENP-I, and HEC1 (Figure 5d and f) and the proper alignment of chromosomes (Figure 5e and f) . In addition, the endogenous level of SGT1 protein was unaffected by 17-AAG treatment (Figure 6a) , and overexpression of SGT1A did not substantially affect cell cycle progression (Figure 5g and h) . These results indicate that overexpression of SGT1A specifically complements the kinetochore defects induced by 17-AAG. Importantly, these results exclude the possibility that the kinetochore defects are induced by side effects of 17-AAG rather than inhibition of HSP90.
Taken together, these results strongly suggest that HSP90 functions, via SGT1, to assemble the kinetochore in human cells.
PLK1 or survivin does not appear to be involved in the kinetochore assembly mechanism via the HSP90-SGT1 complex de Carcer (2004) has proposed that GA induces mitotic delay by inhibiting polo-like kinase (PLK1). However, PLK1 levels were not substantially affected by 17-AAG at the concentrations at which kinetochore proteins were delocalized and mitosis was delayed (Figure 6a) . Furthermore, overexpression of PLK1 did not suppress these kinetochore defects, though overexpression of SGT1 under the same conditions did (Figure 6b , c, and e). These results strongly suggest that depletion of PLK1 by 17-AAG, at least at the concentrations that we used, is not the essential factor in the induction of kinetochore defects.
HSP90 interacts with survivin (an apoptosis inhibitor and an essential chromosomal passenger protein) (Fortugno et al., 2003) . Survivin plays a role in recruiting aurora B and INCENP to kinetochores (Carvalho et al., 2003; Lens et al., 2003) . Therefore, we examined survivin's involvement in the kinetochore defects induced by 17-AAG. Indeed, survivin levels were decreased by addition of 17-AAG (Figure 6a ). However, overexpression of survivin did not restore antibody, subjected to SDS-PAGE (4%-15%), and stained with SYPRO Ruby. Gel slices containing proteins of potential interest were excised, and the proteins were identified by mass spectrometry. The sequences identifed represented 30% of the complete sequence of HSP90alpha, 29% of HSP90beta, and 17% of HSC70. (b) Immunoblot analysis of SGT1 immunoprecipitates. Proteins in the cell lysate (input, IN), supernatant (S), and precipitate (P) obtained by using an anti-SGT1 antibody or mouse IgG were detected with antibodies to SGT1, HSP90, HSC70, SKP1, survivin, aurora A, aurora B, and CDC37. The volume of the total cell lysate was equivalent to 5 or 10% of that of the starting material. (c) Immunoblot analysis of HSP90 immunoprecipitates. Cell lysates were immunoprecipitated with the anti-HSP90 antibody or mouse IgG, and proteins in the lysates, supernatants, and immunoprecipitates were detected with antibodies to SGT1 or HSP90 as in (b), but the total cell lysate volume was equivalent to 2% of that of the starting material. (d) 17-AAG treatment but not DMSO inhibits HSP90-SGT1 association. HeLa cells were treated with 17-AAG (at 500 nM) or DMSO for 24 h before immunoprecipitation with antibody to SGT1. Pc: control immunoprecipitates obtained by using mouse IgG. Immunoblot analysis was performed as described in (c). (e) Immunoblot analysis of SGT1 immunoprecipitates from lysates of asynchronous cells (Asyn), doublethymidine blocked cells (Thy), and TN16-treated cells (TN16). Proteins in the cell lysate (IN) and in the precipitate (P) obtained by using an anti-SGT1 antibody were detected with antibodies to SGT1 and to HSP90. Total cell lysate (IN) volume was equivalent to 0.5% of that of the starting material. FACS profiles (lower panels) are also shown.
HSP90 is required for human kinetochore assembly Y Niikura et al the kinetochore localization of CENP-H (Figure 6b ) or the mitotic delay induced by 17-AAG (Figure 6c ). In addition, overexpression of SGT1A, which restored the kinetochore defects induced by 17-AAG, did not restore the protein levels of survivin that were reduced by 17-AAG (Figure 6f ). Therefore, survivin does not appear to be involved in the HSP90-SGT1 pathway. This conclusion is supported by the absence of survivin from the SGT1 immunoprecipitate (Figure 4b ).
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Discussion
We report a novel mechanism by which 17-AAG inhibits cell proliferation. We have shown that inhibition of HSP90 by 17-AAG or depletion of HSP90 by specific siRNA causes the delocalization of particular kinetochore proteins including CENP-H and CENP-I. We found that HSP90 interacts with SGT1 in human cells. Depletion of SGT1 sensitizes cells to 17-AAG, and overexpression of SGT1 can suppress the kinetochore defects induced by 17-AAG. These results strongly suggest that HSP90, through SGT1, participates in kinetochore assembly in human cells.
Hsp90 is required for kinetochore assembly in yeast and humans In budding yeast, Sgt1, with Skp1, is required for assembly of the core kinetochore complex (CBF3) via Ctf13 activation, although Sgt1 is not a kinetochore component (Kitagawa et al., 1999 (Bansal et al., 2004) . These results and the findings by Lingelbach and Kaplan (2004) suggest that Sgt1 and Hsp90 function in the assembly of CBF3 by activating Skp1 and Ctf13. An important question is whether the core kinetochore complex in humans is similar to CBF3 in budding yeast. As the structure of human centromere DNA, which consists of repetitive alpha-satellite sequences that are several kilobases to megabases long, is very different from that of the yeast point centromere and because yeast CBF3 components (except Skp1) are not conserved in humans (Kitagawa and Hieter, 2001; Biggins and Walczak, 2003) , a CBF3-like complex may not be present in human kinetochores.
However, human SGT1 rescues the lethal phenotype of the yeast sgt1-null mutant (Kitagawa et al., 1999) . CENP-I, CENP-F, and HEC1, but not CENP-C, are absent from kinetochores in SGT1-depleted HeLa cells, a finding that further supports the hypothesis that SGT1 is crucial in the assembly of human kinetochores (Steensgaard et al., 2004) . Also noteworthy is the fact that HSP90 is highly conserved from yeast to human (Piper et al., 2003) . We found that SGT1 interacts with HSP90 in human cells, and our data suggest that HSP90 is required for the assembly of human kinetochores. Therefore, the mechanism of kinetochore assembly by the HSP90-SGT1 complex is probably also conserved from yeast to human. On the basis of our findings, we propose a model of HSP90-SGT1 function in humans that is analogous to that proposed for yeast (Figure 6g ). In the model, HSP90-SGT1 activates an unknown core kinetochore protein X; this activation leads to the assembly of kinetochore complexes (Figure 6g ). Protein X in humans corresponds to the yeast's Ctf13 (the CBF3 F-box protein) (Bansal et al., 2004) . Geldanamycin inhibits activation by binding to HSP90 ( Figure 6g) ; this proposed step is supported by the finding that 17-AAG disrupts the HSP90-SGT1 interaction (Figure 4d ). We have not found any interactions between known kinetochore proteins and the HSP90-SGT1 complex (Figure4b and Supplementary Figure S3c) . In the present study, depletion of SGT1 sensitized human cells to 17-AAG, and 17-AAG disrupted the SGT1-HSP90 interaction. Therefore, SGT1 or the HSP90-SGT1 complex might be an attractive target for cancer therapy.
HSP90 is required for kinetochore assembly from late S phase to G2/M phase Pharmacologic inhibition of HSP90 allowed us to determine the time point at which HSP90 function is required for kinetochore assembly. This type of finding is not readily obtainable by other methods such as siRNA treatment, antibody injection, or the use of inducible promoter systems. When cells were treated with 17-AAG for 2 h during 6-8 h (late S phase to G2/M phase) after the introduction of a double-thymidine block at G1/S phase, the kinetochore localization of CENP-H and CENP-I was substantially reduced (Figure 3b and c) . Therefore, HSP90 must function at this particular cell cycle stage in the assembly of kinetochore complexes. This finding is consistent with the fact that centromeric alpha-satellite DNA sequences 0 is necessary for the assembly of additional kinetochore complexes. GA inhibits the HSP90-SGT1 association; thus, activation of X is inhibited.
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Y Niikura et al replicate late in S phase (Ten Hagen et al., 1990) . As 17-AAG treatment at prometaphase or metaphase did not affect kinetochore localization of CENP-H or CENP-I (Figure 3b and c) , the time in which HSP90 is required for kinetochore assembly most probably precedes metaphase. Interestingly, 17-AAG treatment caused greater delocalization of BUBR1, CENP-E, and HEC1 from kinetochores during metaphase than during prophase or prometaphase (Figure 1e ). This result suggests that HSP90 may function at two time points in kinetochore assembly: one before prophase that involves the assembly of complexes containing CENP-H, and CENP-I, and another after prophase that involves the assembly of complexes containing BUBR1, CENP-E, and HEC1.
17-AAG affects the kinetochore localization of particular kinetochore proteins differently Treatment with 17-AAG, HSP90 siRNA, or SGT1 siRNA affected the kinetochore localization of CENP-H most drastically but did not substantially affect that of CENP-C or CENP-B (Steensgaard et al., 2004) . CENP-B binds directly to alpha-satellite DNA (Masumoto et al., 1989; Yoda et al., 1996) . This structural difference may explain our finding that 17-AAG does not affect the kinetochore localization of CENP-B. However, Fukagawa et al. (2001) reported that CENP-H is required for the targeting of CENP-C to kinetochores in chicken cells. This discrepancy may be explained by differences between chicken and human cells. Another possibility is that because only a 'helper' such as HSP90 or SGT1 was inhibited, not the kinetochore protein itself, CENP-H may not have to be at the kinetochore to recruit (or maintain) CENP-C. Alternatively, CENP-H may have been present in sufficient quantity to initiate the assembly of kinetochore complexes despite its substantial reduction at kinetochores in 17-AAG-treated cells.
17-AAG treatment did not substantially disrupt kinetochore ultrastructure or kinetochore-microtubule attachment Despite the delocalization of several kinetochore proteins, electron microscopy revealed that 17-AAG treatment did not substantially affect the kinetochore's ultrastructure or kinetochore-microtubule attachment (Supplementary Figure S4) . The mean number of microtubules bound per kinetochore was 14 (range, 11-18; counted in 35 cells) . This number is somewhat less than the 16.9 we observed previously in untreated HeLa cells, but it is similar to the 15.6 we observed in mock-transfected HeLa cells (McEwen et al., 2001; DeLuca et al., 2005) . Only 12.5 microtubules bound per kinetochore were observed in CENP-E-depleted HeLa cells whose chromosomes had achieved metaphase alignment (McEwen et al., 2001) . Therefore, we conclude that the number of microtubules bound to kinetochores in 17-AAG-treated HeLa cells was enough to support relatively normal chromosome movement. A subtle reduction in the number of kinetochoreattached microtubules may be sufficient to activate the spindle checkpoint and to cause moderate chromosome misalignment and aneuploidy.
Materials and methods

Plasmid construction and primers
The cDNA encoding full-length human SGT1A (SUGT1A) with a C-terminal Flag tag was cloned into the pTRM4 yeastmammalian shuttle vector (Kitagawa and Abdulle, 2002) , which results in B1167. Details of the construction of plasmids and sequences of primers are available upon request.
siRNA We designed and used SGT1A siRNA (5 0 -GCUAGAGGGG CAAGGAGAUTT-3 0 ). We obtained similar data by using another target sequence (Steensgaard et al., 2004) . The siRNAs that target MAD2 and luciferase have been described (Elbashir et al., 2001; Martin-Lluesma et al., 2002) . Similar data were obtained when these two independent sets of siRNAs were used. The siRNAs that target SGT1 and MAD2 were synthesized by the Hartwell Center for Bioinformatics and Biotechnology at St Jude Children's Research Hospital. The siRNA oligonucleotides that target HSP90a and HSP90b were purchased from Ambion, Inc. (Austin, TX, USA).
Cell culture and transfection
All human cell lines were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). HeLa cells were cultured in high-glucose Dulbecco's modified Eagle's medium (BioWhittaker, Walkersville, MD, USA) with 10% fetal bovine serum (Invitrogen, Carlsbad, CA, USA), and HCT116 cells were grown in McCoy's 5A medium (ATCC) with 10% fetal bovine serum. All cell lines were grown at 371C in 5% CO 2 in a humidified incubator. Cells were transfected with annealed double-stranded siRNA or mammalian expression plasmids by using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) or Fugene 6 (Roche, Indianapolis, IN, USA).
The double-thymidine block was implemented as described (Tatsumi et al., 2003) . Procedures to collect mitotic cells for immunoprecipitation were essentially as described (Tatsumi et al., 2003) . In brief, cells were subjected to the doublethymidine block procedure and then cultured in the presence of 0.5 mM TN16 (Biomol, Plymouth Meeting, PA, USA) for 12 h.
Antibodies
Supplementary Table 1 lists the antibodies used in this study.
Immunoblotting
The method of immunoblotting has been described (Lamb et al., 1995) . Cells were added to lysis buffer A (Panaretou et al., 2002) , then the mixture was frozen in liquid nitrogen, thawed, and sonicated. Before electrophoresis, cell lysates were mixed with an equal volume of 2 Â SDS sample buffer (Lamb et al., 1995) .
Immunofluorescence assay
We slightly modified methods of indirect immunofluorescent staining that have been described Yoda et al., 1996 (Taylor et al., 2001 ) have been described. Immunofluorescence studies using the anti-MAD2 antibody were performed as described (Andreassen et al., 2004) .
To quantify kinetochore signals (kinetochore remaining signals of each kinetochore colocalized protein), we applied the same method previously described with minor modification (Meraldi and Sorger, 2005; Yang et al., 2005) . The percentage of remaining signal at the kinetochore was quantified by Openlab 4.0.1. and Volocity software programs (Improvision, Lexington, MA, USA) using the formula Remaining kinetochore signal with s (signal brightness of the selected area where is confirmed by CREST staining), b (background signal brightness), r (reference signal), sample (drug-treated or siRNA-transfected cells), ctrl (drug nontreated or luciferase siRNA-transfected cells). For each measurement, levels in at least n ¼ 20 cells were determined to eliminate variations in staining and image acquisition.
Electron microscopy
Electron microscopy was performed by the Wadsworth Core Facility. HeLa cells on coverslips were prepared for electron microscopy as described previously (McEwen et al., 1997) . Briefly, the cells were fixed with 2% glutaraldehyde and 2% OsO 4 , stained and blocked with tannic acid and uranyl acetate, dehydrated with a graded ethanol series, and embedded in Epon resin. Embedded specimens were cut into 80-100-nmthick serial sections, and images were obtained and recorded, at a magnification of Â 6300, by using a Zeiss 910 electron microscope operated at 100 kV. The numbers of microtubules attached to individual kinetochores were counted in serial micrographs and recorded as described previously (McEwen et al., 1997 (McEwen et al., , 2001 ).
Immunoprecipitation assays
We obtained extracts of HeLa cells cultured in 100-mm dishes by rinsing them three times with ice-cold PBS and lysing the cells in ice-cold buffer A (40 mM HEPES (pH 7.5), 120 mM NaCl, 1 mM EDTA, 1% Triton-X100, and one tablet of EDTA-free protease inhibitor cocktail (Roche) per 10 ml) for 30 min on ice. The numbers of cells in each sample used in SGT1 and HSP90 immunoprecipitation experiments were 4 Â 10 7 cells and 1 Â 10 6 cells, respectively. After centrifugation (20 800g for 5 min at 41C) of the lysates, SGT1 and HSP90, which were in the supernatant fraction, were precipitated by using 4 mg of anti-SGT1 antibody (BD Biosciences; San Jose, CA, USA) and of anti-HSP90 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), respectively. After each mixture was incubated at 41C for 2 h, 10 ml of protein A-Sepharose (Amersham Biosciences, Piscataway, NJ USA) was added, and the mixtures were incubated at 41C for 1 h. Immunoprecipitates were washed five times with Buffer A, and the precipitated protein was eluted in SDS sample buffer (50 mM Tris-HCl (pH 6.8), 2% SDS, 0.1% bromophenol blue, and 10% glycerol).
Chromosome counts
Chromosomes were counted at the St Jude Cytogenetics facility as previously described (Drouin et al., 1988) . Exponentially growing HCT116 human colon cancer cells were treated with 500 nM 17-AAG (AG Scientific, San Diego, CA, USA) for 24 h, and the drug was removed by washing. Chromosomes in 100 metaphase cells in each sample (cells treated with 500 nM 17-AAG and untreated cells) were scored by direct microscopic examination.
Mass spectrometry
All procedures were performed as previously described (Bansal et al., 2004) . Mass spectrometry (under the direction of Clive Slaughter) was performed at the Hartwell Center for Bioinformatics and Biotechnology. SGT1 immunoprecipitated from 4 Â 10 7 HeLa cells was subjected to SDS-PAGE, and proteins in excised gel pieces were reduced, alkylated with iodoacetamide, and digested with trypsin. The unfractionated digest was subjected to mass spectrometry, and the mass values of the peptides were matched with values expected by analysis of the protein sequence. Mass spectrometry of the digested protein in a crystalline matrix of alpha-cyano-4-hydroxycinnamic acid was performed by matrix-assisted laser desorption/ionization used in conjunction with tandem time-of-flight mass analysis in a 4700 Proteomics Analyzer from Applied Biosystems (Foster City, CA, USA). Database searches were performed with Applied Biosystems GPS explorer software, which uses the Mascot search engine. Protein assignments were based on MS and MS/MS spectra. The National Center for Biotechnology Information nonredundant (NCBInr) protein database was used for protein identification.
Colony outgrowth assay
The colony outgrowth assay was performed as described previously (Blasco et al., 1997; Reilly et al., 2002; Kranc et al., 2003) with a minor modification. At 24 h after siRNA transfection, the cells were incubated with 100 nM 17-AAG for 4 days. This condition was chosen to avoid cytotoxicity. The drug was then removed by washing. Next, 500 transfected cells were spread in one well of a six-well cluster (Corning Costar, Acton, MA, USA) and incubated for 40 days to allow colony formation. Giemsa-stained (HEMA-QUIK stain solution, Fisher Scientific, Hampton, NH, USA) colonies were counted. The viability (%) was normalized; the percentage of surviving colonies of untreated cells transfected with control luciferase siRNA was arbitrarily set to 100.
Apoptosis assays
At 48 h after siRNA transfection, HeLa cells were incubated with 500 nM 17-AAG for 24 h. Cells were fixed with 4% HSP90 is required for human kinetochore assembly Y Niikura et al paraformaldehyde in PBS (pH 7.4), and the TUNEL assay was performed by using an in situ cell-death detection kit that contained TMR red (Roche).
